| Author(s) | Ip C; Banni S; Angioni E; Carta G; McGinley J; Thompson HJ; Barbano D; Bauman D
|
|---|
| Title | Conjugated linoleic acid-enriched butter fat alters mammary gland morphogenesis and reduces cancer risk in rats
|
|---|
| Source | JOURNAL OF NUTRITION 129 (12): 2135-2142
|
|---|
| Date | 1999 DEC
|
|---|
| Type | Journal : Article
|
|---|
| LCR: 15 NCR: 32 LCS: 67 GCS: 136
| | Comment |
|
|---|
| Address | Roswell Pk Canc Inst, Dept Expt Pathol, Buffalo, NY 14263 USA.
Univ Cagliari, Dipartimento Biol Sperimentale, I-09042 Cagliari, Italy.
AMC Canc Res Ctr, Div Lab Res, Denver, CO USA.
Cornell Univ, Dept Food Sci, Ithaca, NY 14853 USA.
Cornell Univ, Dept Anim Sci, Ithaca, NY 14853 USA.
|
|---|
| Reprint | Ip, C, Roswell Pk Canc Inst, Dept Expt Pathol, Buffalo, NY 14263 USA.
|
|---|
| Abstract | Conjugated linoleic acid (CLA) is a potent cancer preventive agent in animal models. To date, all of the in vivo work with CLA has been done with a commercial free fatty acid preparation containing a mixture of c9,t11-, t10,c12-and c11,t13-isomers, although CLA in food is predominantly (80-90%) the c9,t11-isomer present in triacylglycerols. The objective of this study was to determine whether a high CLA butter fat has biological activities similar to those of the mixture of free fatty acid CLA isomers. The following four different endpoints were evaluated in rat mammary gland: 1) digitized image analysis of epithelial mass in mammary whole mount; 2) terminal end bud (TEB) density; 3) proliferative activity of TEE cells as determined by proliferating cell nuclear antigen immunohistochemistry; and 4) mammary cancer prevention bioassay in the methylnitrosourea model. It should be noted that TEE cells are the target cells for mammary chemical carcinogenesis. Feeding butter fat CLA to rats during the time of pubescent mammary gland development reduced mammary epithelial mass by 22%, decreased the size of the TEE population by 30%, suppressed the proliferation of TEE cells by 30% and inhibited mammary tumor yield by 53% (P < 0.05). Furthermore, all of the above variables responded with the same magnitude of change to both butter fat CLA and the mixture of CLA isomers at the level of CLA (0.8%) present in the diet. Interestingly, there appeared to be some selectivity in the uptake or incorporation of c9,t11-CLA over t10,c12-CLA in the tissues of rats given the mixture of CLA isomers. Rats consuming the CLA-enriched butter fat also consistently accumulated more total CLA in the mammary gland and other tissues (four-to sixfold increases) compared with those consuming free fatty acid CLA (threefold increases) at the same dietary level of intake. We hypothesize that the availability of vaccenic acid (t11-18:1) in butter fat may serve as the precursor for the endogenous synthesis of CLA via the Delta 9-desaturase reaction. Further studies will be conducted to investigate other attributes of this novel dairy product.
|
|---|
| CR |
BANNI S, 1994, J AM OIL CHEM SOC, V71, P1321
BANNI S, 1996, J NUTR BIOCHEM, V7, P150
BANNI S, 1998, T FATTY ACIDS HUMAN, P261
BANNI S, 1999, CARCINOGENESIS, V20, P1019
BAUMGARD L, 1999, IN PRESS AM J PHYSL
BELURY MA, 1996, NUTR CANCER, V26, P149
CESANO A, 1998, ANTICANCER RES, V18, P1429
CHOUINARD PY, 1999, J NUTR, V129, P1579
CHRISTIE WW, 1982, J LIPID RES, V23, P1072
FOLCH J, 1957, J BIOL CHEM, V226, P497
GRIINARI JM, 1999, CONJUGATED LINOLEIC, P180
HA YL, 1990, CANCER RES, V50, P1097
HORVATH PM, 1983, CANCER RES, V43, P5335
IP C, 1987, AM J CLIN NUTR, V45, P218
IP C, 1994, CANCER, V74, P1051
IP C, 1995, NUTR CANCER, V24, P241
IP C, 1996, CARCINOGENESIS, V17, P1045
IP C, 1997, AM J CLIN NUTR, V66, P1523
IP MM, 1999, EXP CELL RES, V250, P22
KELLY ML, 1998, J NUTR, V128, P881
KRAMER JKG, 1998, LIPIDS, V33, P549
LIEW C, 1995, CARCINOGENESIS, V16, P3037
MOYACAMARENA SY, 1999, BBA-MOL CELL BIOL L, V1436, P331
MOYACAMARENA SY, 1999, J LIPID RES, V40, P1426
PARK Y, 1999, LIPIDS, V34, P235
PARODI PW, 1997, J NUTR, V127, P1055
RUSSO J, 1978, J NATL CANCER I, V61, P1451
SEBEDIO JL, 1997, BBA-LIPID LIPID MET, V1345, P5
SEHAT N, 1998, LIPIDS, V33, P217
THOMPSON H, 1997, CANCER RES, V57, P5067
VISONNEAU S, 1997, ANTICANCER RES, V17, P969
ZHU ZJ, 1998, CARCINOGENESIS, V19, P2101
|
|---|
|